CytoDyn (OTCQB:CYDY) treated the first patient in its Phase 2 basket trial of leronlimab for the treatment of some 22 different types of solid cancer tumors.
This Phase 2 trial will enroll 30 patients with CCR5+ locally advanced or metastatic solid tumors. Patients will receive a 350 mg injection of subcutaneous leronlimab weekly, in addition to the standard-of-care chemotherapy, as determined by the treating physician.
Preliminary results on each patient are expected within three-to-four weeks after the initial injection of leronlimab. The trial’s primary endpoint is progression-free survival.
“The results so far in triple-negative breast cancer and HER-2+ breast cancer patients have remarkably demonstrated the shrinking of primary tumors, the shrinking or elimination of metastatic lesions, and the reduction of circulating tumor cells to zero, which has remained stable over several weeks,” Dr. Bruce Patterson, CEO and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn, said in a statement.
“Further, these data help define the relationship between CCR5 on immune cell infiltrates and response as we analyze these responding patients. Based on histologic findings in other cancers, we are hopeful that this response translates to the other tumors in this trial,” he added.
